PURPOSE: We investigated survival potential in patients receiving erlotinib after failure of
gefitinib, focusing on response and time to progression (TTP) with gefitinib. METHODS: We …

Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …

Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Among treatment modalities for lung cancer, the most promising therapy is the use of
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and …

Introduction: Patients with epidermal growth factor receptor (EGFR) mutation positive non–
small-cell lung cancer exhibited marked response to gefitinib or erlotinib. In most cases …

Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and
erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung …

Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …

Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …